CD80 and carcinoma: We then immunolocalized B7‐1 and PD‐L1 in both primary to metastatic NSCLC lesions of the patients and compared the findings between them with correlation to the status of immune cells around carcinoma cells to further explore the clinicopathological significance of B7‐1 in NSCLC.